This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cesarone, M. R. Articles by Corsi, M. Search for Related Content PubMed PubMed Citation Articles by Cesarone, M. R. Articles by Corsi, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton®): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

G. Belcaro, PhD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy, cardres{at}pe.abol.it

L. Pellegrini, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

A. Ledda, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

G. Vinciguerra, PhD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

A. Ricci, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

G. Gizzi, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

E. Ippolito, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

F. Fano, MB

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

M. Dugall, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

G. Acerbi, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

M. Cacchio, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

A. Di Renzo, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

S. Stuard, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

M. Corsi, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D’Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L’Aquila University, Italy

The aim of this independent study was to demonstrate the rapidity of the clinical action of HR 0-(beta-hydroxyethyl)-rutosides, Venoruton^® (Novartis Consumer Health) in patients with chronic venous insufficiency (CVI). Two groups of patients with venous hypertension and microangiopathy were treated with HR (1 or 2 g/day, for 8 weeks). Twelve patients (age 56.4; range 44-66; M:F = 6:6) were included in group 1 (1 g/day) (moderate CVI and microangiopathy); 10 patients (age 57.4; range 42-67; M:F = 5:5) in group 2 (2 g/day) with more severe CVI and microangiopathy. Average ambulatory venous pressure (AVP) was 58.6 (range 50-65) with a refilling time (RT) shorter than 10 seconds. There were no significant differences in AVP and RT between the 2 groups, but the duration of the disease was longer in group 2: 3.5 years (SD 2.0) in group 1 and 6.4 years (SD 3.3) in group 2. All included subjects completed the study and no dropouts were observed. In both dose groups there was a progressive decrease in laser Doppler resting flux (RF), indicating improvement in microangiopathy and a significant decrease in capillary filtration (RAS) associated with a significant improvement in analogue scale line score (ASLS) and edema. Although the effect in the 2 g dose group was more rapid on the microcirculatory parameters with a significant effect on RF and RAS after 4 days (effect of 1 g per day after 8 days and 6 days, respectively), there was no difference in the time to onset of a significant clinical improvement (ie, the ASLS and the edema score): 4 days in both groups. Venous microangiopathy and edema were improved by the treatment with HR within a few days. The effects were visible with both dosages, in both severity groups.

Angiology, Vol. 56, No. 2, 165-172 (2005)
DOI: 10.1177/000331970505600207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. R. Cesarone, G. Belcaro, and M. G. Grossi O-({beta}-Hydroxyethyl)-Rutosides (Paroven; Venoruton): New Studies, Improved Safety, and Novel Cardiovascular Applications Angiology, March 1, 2008; 59(1_suppl): 5S - 6S. [PDF]

				G. Belcaro, M. Rosaria Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. O-({beta}-Hydroxyethyl)-Rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: An Independent Prospective Comparative Study Angiology, March 1, 2008; 59(1_suppl): 7S - 13S. [Abstract] [PDF]

				G. Belcaro, M. R. Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. 5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-({beta}-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry Angiology, March 1, 2008; 59(1_suppl): 14S - 20S. [Abstract] [PDF]

				U. Wollina, M. B. Abdel-Naser, and R. Mani A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 169 - 180. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 93 - 99. [Abstract] [PDF]